

Ruben Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1027530/publications.pdf>

Version: 2024-02-01

93
papers

7,580
citations

47006

47
h-index

74163

75
g-index

101
all docs

101
docs citations

101
times ranked

6678
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. <i>Nature Medicine</i> , 2020, 26, 379-386.	30.7	643
2	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 772.	7.4	640
3	Four distinct trajectories of tau deposition identified in Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 871-881.	30.7	354
4	Discriminative Accuracy of [¹⁸ F]florbetapir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1151.	7.4	298
5	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 2612.	12.8	283
6	Increased sperm DNA damage in patients with varicocele: relationship with seminal oxidative stress. <i>Human Reproduction</i> , 2006, 21, 986-993.	0.9	273
7	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 1683.	12.8	252
8	Orexin loss in Huntington's disease. <i>Human Molecular Genetics</i> , 2005, 14, 39-47.	2.9	246
9	A β 2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. <i>Science Advances</i> , 2020, 6, eaaz2387.	10.3	202
10	Plasma GFAP is an early marker of amyloid- β 2 but not tau pathology in Alzheimer's disease. <i>Brain</i> , 2021, 144, 3505-3516.	7.6	198
11	Associations between tau, A β 2, and cortical thickness with cognition in Alzheimer disease. <i>Neurology</i> , 2019, 92, e601-e612.	1.1	196
12	Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 347.	12.8	185
13	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 149.	9.0	176
14	¹⁸ F-AV-1451 and CSF T α tau and P α tau as biomarkers in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2017, 9, 1212-1223.	6.9	156
15	¹⁸ F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. <i>Brain</i> , 2016, 139, 2372-2379.	7.6	149
16	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. <i>Brain</i> , 2017, 140, 2286-2294.	7.6	149
17	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 961.	9.0	148
18	Synaptic dysfunction in Huntington's disease: a new perspective. <i>Cellular and Molecular Life Sciences</i> , 2005, 62, 1901-1912.	5.4	141

#	ARTICLE	IF	CITATIONS
19	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. <i>JAMA Neurology</i> , 2020, 77, 955.	9.0	136
20	Untangling the association of amyloid- β^2 and tau with synaptic and axonal loss in Alzheimer's disease. <i>Brain</i> , 2021, 144, 310-324.	7.6	123
21	Cholinergic neuronal defect without cell loss in Huntington's disease. <i>Human Molecular Genetics</i> , 2006, 15, 3119-3131.	2.9	117
22	Increased metabolism in the R6/2 mouse model of Huntington's disease. <i>Neurobiology of Disease</i> , 2008, 29, 41-51.	4.4	114
23	Increased basal ganglia binding of ¹⁸ F-AV-1451 in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 2017, 32, 108-114.	3.9	111
24	Mood changes, obstetric experience and alterations in plasma cortisol, beta-endorphin and corticotrophin releasing hormone during pregnancy and the puerperium. <i>Journal of Psychosomatic Research</i> , 1990, 34, 53-69.	2.6	104
25	In vivo retention of ¹⁸ F-AV-1451 in corticobasal syndrome. <i>Neurology</i> , 2017, 89, 845-853.	1.1	103
26	Soluble p-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. <i>EMBO Molecular Medicine</i> , 2021, 13, e14022.	6.9	90
27	Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks. <i>Frontiers in Neuroscience</i> , 2017, 11, 167.	2.8	87
28	Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer's disease. <i>Science Advances</i> , 2020, 6, .	10.3	86
29	Predicting diagnosis and cognition with ¹⁸ F-AV-1451 tau PET and structural MRI in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 570-580.	0.8	84
30	Correlation of In Vivo [¹⁸ F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology. <i>JAMA Neurology</i> , 2019, 76, 310.	9.0	84
31	Comparing ¹⁸ F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , 2018, 90, e388-e395.	1.1	83
32	Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 13986-13991.	7.1	82
33	The implications of different approaches to define AT(N) in Alzheimer disease. <i>Neurology</i> , 2020, 94, e2233-e2244.	1.1	80
34	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 632.	9.0	80
35	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 76.	4.8	78
36	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. <i>Brain</i> , 2021, 144, 2771-2783.	7.6	78

#	ARTICLE	IF	CITATIONS
37	Loss of SNAP-25 and rabphilin 3a in sensory-motor cortex in Huntington's disease. <i>Journal of Neurochemistry</i> , 2007, 103, 070630082917008-???	3.9	75
38	Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 335-344.	0.8	73
39	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 149.	9.0	66
40	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. <i>Brain</i> , 2020, 143, 3805-3815.	7.6	65
41	Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2017, 133, 149-151.	7.7	61
42	Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 342-354.	6.4	61
43	18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies. <i>Scientific Reports</i> , 2018, 8, 4717.	3.3	59
44	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma tau biomarkers. <i>EMBO Molecular Medicine</i> , 2021, 13, e14398.	6.9	58
45	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. <i>ELife</i> , 2019, 8, .	6.0	57
46	Greater tau load and reduced cortical thickness in APOE ϵ 4-negative Alzheimer's disease: a cohort study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 77.	6.2	56
47	Modeling Strategies for Quantification of In Vivo ¹⁸ F-AV-1451 Binding in Patients with Tau Pathology. <i>Journal of Nuclear Medicine</i> , 2017, 58, 623-631.	5.0	53
48	Mutant huntingtin interacts with α -tubulin and disrupts vesicular transport and insulin secretion. <i>Human Molecular Genetics</i> , 2009, 18, 3942-3954.	2.9	43
49	The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. <i>Neurobiology of Aging</i> , 2015, 36, 1736-1742.	3.1	42
50	A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2295-2305.	6.4	41
51	Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction. <i>Neurobiology of Disease</i> , 2005, 20, 673-684.	4.4	33
52	Tyrosine hydroxylase expression is unstable in a human immortalized mesencephalic cell line—Studies in vitro and after intracerebral grafting in vivo. <i>Molecular and Cellular Neurosciences</i> , 2007, 34, 390-399.	2.2	30
53	Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 339-343.	2.6	30
54	NGF Rescues Hippocampal Cholinergic Neuronal Markers, Restores Neurogenesis, and Improves the Spatial Working Memory in a Mouse Model of Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2013, 2, 69-82.	1.9	28

#	ARTICLE	IF	CITATIONS
55	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2245-2258.	6.4	27
56	18F-Flortaucipir in TDP-43 associated frontotemporal dementia. <i>Scientific Reports</i> , 2019, 9, 6082.	3.3	26
57	Tau PET Imaging in Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2022, 63, 20S-26S.	5.0	26
58	The <i>BIN1</i> rs744373 Alzheimer's disease risk SNP is associated with faster $A\beta$ -associated tau accumulation and cognitive decline. <i>Alzheimer's and Dementia</i> , 2022, 18, 103-115.	0.8	24
59	Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people. <i>Alzheimer's and Dementia</i> , 2018, 14, 54-61.	0.8	21
60	Sex differences in off-target binding using tau positron emission tomography. <i>NeuroImage: Clinical</i> , 2021, 31, 102708.	2.7	21
61	Derivation and utility of an $A\beta$ -PET pathology accumulation index to estimate $A\beta$ load. <i>Neurology</i> , 2020, 95, e2834-e2844.	1.1	14
62	Reappraisal of the hypo-osmotic swelling test to improve assessment of seminal fertility status. <i>Journal of Developmental and Physical Disabilities</i> , 1992, 15, 5-13.	3.6	13
63	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2259-2271.	6.4	10
64	Compensating for choroid plexus based off-target signal in the hippocampus using 18F-flortaucipir PET. <i>NeuroImage</i> , 2020, 221, 117193.	4.2	9
65	The Effect of Repetitive Haemorrhage on Plasma Cortisol, Beta-Endorphin and N-Terminal Pro-Opiomelanocortin in Conscious Sheep. <i>Hormone and Metabolic Research</i> , 1988, 20, 612-615.	1.5	6
66	Mild behavioral impairment is predictive of tau deposition in the earliest stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042595.	0.8	6
67	[18F]Flortaucipir distinguishes Alzheimer's disease from progressive supranuclear palsy pathology in a mixed-pathology case. <i>Acta Neuropathologica</i> , 2020, 139, 411-413.	7.7	6
68	Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2223-2232.	4.3	5
69	No symphony without bassoon and piccolo: changes in synaptic active zone proteins in Huntington's disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 77.	5.2	4
70	Phospho-tau217 and phospho-tau181 in plasma and CSF as biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037520.	0.8	2
71	The accumulation rate of tau aggregates is higher in females and younger individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, e043876.	0.8	2
72	BDNF improves the spatial working memory in R6/1 Huntington's disease transgenic mice through the augmentation of cholinergic function and neurogenesis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, A16.4-A16.	1.9	1

#	ARTICLE	IF	CITATIONS
73	Operative Outcomes with Myxomatous Mitral Valve Repair: Experience with 586 Patients. Heart Lung and Circulation, 2016, 25, 870-873.	0.4	1
74	Optimized regional analysis to detect longitudinal 18 F-RO-948 tau PET change in early AD. Alzheimer's and Dementia, 2020, 16, e045765.	0.8	1
75	Plasma glial fibrillary acidic protein is an early and specific marker of amyloid- β^2 pathology in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	1
76	P4-339: Early and Late Onset Alzheimer's Disease are Associated with Distinct Regional TAU Pathology as Examined with [18]F-AV-1451 TAU Positron Emission Tomography. Alzheimer's and Dementia, 2016, 12, P1164.	0.8	0
77	P3-224: Age-Related Increase in Basal Ganglia Binding of 18 F-AV1451 in Healthy Elderly and Patients with Progressive Supranuclear Palsy. , 2016, 12, P911-P911.		0
78	IC-01-04: 18 F-AV1451 Pet Detects TAU Pathology in MAPT Mutation Carriers and Correlates Strongly with Immunohistochemistry of TAU Aggregates. , 2016, 12, P3-P4.		0
79	P2-254: ¹⁸ F-AV1451 PET DETECTS TAU PATHOLOGY IN MAPT MUTATION CARRIERS AND CORRELATES STRONGLY WITH IMMUNOHISTOCHEMISTRY OF TAU AGGREGATES. Alzheimer's and Dementia, 2016, 12, P723.	0.8	0
80	[IC-P-199]: [18]F-AV-1451 PET IN CLINICALLY DIAGNOSED CORTICOBASAL DEGENERATION. Alzheimer's and Dementia, 2017, 13, P146.	0.8	0
81	[IC-P-195]: SPATIAL CORRESPONDENCE OF ALZHEIMER'S DISEASE-RELATED TAU PATHOLOGY AND GREY MATTER ATROPHY DISTRIBUTION WITH INTRINSIC FUNCTIONAL BRAIN NETWORKS. Alzheimer's and Dementia, 2017, 13, P143.	0.8	0
82	IC-P-218: ¹⁸ F-FLORTAUCIPIR (AV-1451) RETENTION IN PARKINSON'S DISEASE AND DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2018, 14, P178.	0.8	0
83	O3-04-04: ¹⁸ F-FLORTAUCIPIR (AV-1451) RETENTION IN PARKINSON'S DISEASE AND DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2018, 14, P1020.	0.8	0
84	P1-430: EFFECTS OF APOE ϵ 4 ON TAU, AMYLOID, ATROPHY AND COGNITION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P473.	0.8	0
85	O3-04-01: ASSOCIATIONS BETWEEN TAU, $A\beta^2$ AND CORTICAL THICKNESS WITH COGNITION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1018.	0.8	0
86	DT-01-04: DIAGNOSTIC PERFORMANCE OF [¹⁸ F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDER-2 STUDY. Alzheimer's and Dementia, 2019, 15, P1485.	0.8	0
87	Accounting for systematic spatiotemporal variation improves connectome-based models of tau spreading in human Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e040586.	0.8	0
88	Compensating for choroid plexus based off-target signal in the hippocampus using [18 F]flortaucipir PET. Alzheimer's and Dementia, 2020, 16, e041800.	0.8	0
89	Ability of tau-PET, phospho-tau217, NfL and cortical thickness to predict short-term cognitive decline in early symptomatic Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
90	Unravelling drivers of age- and beta-amyloid-related neurodegeneration in medial temporal lobe atrophy in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	0

#	ARTICLE	IF	CITATIONS
91	Biomarker driven enrichment strategies for tau pathology in AD clinical trials. Alzheimer's and Dementia, 2021, 17, .	0.8	0
92	Potential drivers of age- and beta-amyloid-related neurodegeneration in early and late Alzheimer's Disease regions in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	0
93	[¹⁸ F]RO948 tau PET in bvFTD due to <i>C9orf72</i> and <i>GRN</i> mutations. Alzheimer's and Dementia, 2021, 17, .	0.8	0